We are thrilled to announce that Children’s Tumor Foundation President and Chief Scientific Officer Annette Bakker, PhD, has been announced as a recipient of a 2017 RARE Champion of Hope award.
The NF Registry is delivering on its promise to be a valid and useful tool for both patients and researchers. This is the conclusion of an analysis published in the journal PLOS One in June 2017. Not only are thousands of patients from all over the world contributing their data to the Registry, it is being actively used, and appreciated, by researchers working on all forms of NF.
The NF Research Initiative (NFRI) at Boston Children’s Hospital has two open requests for applications:
Children's Tumor Foundation Research & Development VP Salvo La Rosa was interviewed by Outsourcing-Pharma.com on how disease-focused foundations and contract research organizations (CROs) are working together to bridge the gap between drug discovery and development, a topic that will be addressed at BIO2017, the global event for biotechnology, this week.
The second session of the 2017 NF Conference, chaired by Dr. Ludwine Messiaen and Dr. Miriam Smith, focused on the associations between the complex physical manifestations of NF and the diverse genetic variations observed in NF patients. Understanding these ‘genotype-phenotype correlations’ is important for better management of NF and can potentially also pave the way for targeted therapeutic interventions.